September 20, 2010
LOS ANGELES, September 20, 2010 – KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") today announced that Keith Leonard, President and Chief Executive Officer of KYTHERA, will present at the upcoming UBS Global Life Sciences Conference on Tuesday, September 21, 2010, at 11:00 a.m. EDT. The conference will be held at the Grant Hyatt Hotel in New York City.
“We are very pleased to be participating in this premier investor conference,” said Keith Leonard, President and CEO of KYTHERA. “We look forward to the opportunity to provide an update on our corporate developments and progress with ATX-101, an injectable drug being studied for the reduction of small volumes of fat.”
About KTYHERA Biopharmaceuticals, Inc.
KYTHERA is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. The aesthetic market is characterized by an aging population, increasing discretionary income and an evolution of patient preference towards care that focuses on quality of life. The Company uses the tools of biotechnology to develop prescription therapeutics for this emerging market. KYTHERA has an innovative pipeline, with its lead program in adipolysis (ATX-101) starting Phase 3 trials this year. The Company also has active research programs in facial contouring, pigmentation modulation and hair and fat biology.
For more information about KYTHERA, please visit the Company’s web site at http://www.kytherabiopharma.com.